News Release: Michael Abney joins Hemedex Sales Force as Regional Sales Manager for the Midwest

Posted by on Nov 12, 2013 in News Releases

News Release: Michael Abney joins Hemedex Sales Force as Regional Sales Manager for the Midwest

CAMBRIDGE, Mass. (November 12, 2013) – Hemedex, Inc. is pleased to announce that Michael Abney has joined their Sales Force as Regional Sales Manager as of October 21, 2013. He will cover the Midwest Region,  including , Illinois, Indiana, Iowa, Kentucky, Michigan, Minnesota, Nebraska, Northern Ohio, Pennsylvania, West Virginia, and Wisconsin.

Michael brings 10 years of experience in sales and customer service in the medical device industry.  Previously he served as a Regional Sales Manager for NeuroLogica selling neuroimaging technology. In addition, Michael served hospital administration at two institutions by managing operations for clinical and research teams within neuro-related departments.

“Mike’s experience working in neurological applications in the OR and ICU makes him an exceptional match for selling the Bowman Perfusion Monitor.  His expertise in device sales and clinical administration provides him a sound foundation for success in helping critical care facilities adopt the Hemedex technology,” said H. Frederick Bowman, Ph.D., CEO of Hemedex, Inc.

Michael will be operating from his office in Pittsburgh, PA and his contact information is listed below.   Please contact him if you are interested in learning more about the clinical applications and benefits of the Bowman Perfusion Monitor.

Mike Abney, Regional Sales Manager
P:(412) 742-7244
E: mabney@hemedex.com

 

About Hemedex, Inc.:

Hemedex, Inc. manufactures patient monitoring technology, the Bowman Perfusion Monitor®, for quantifying tissue blood flow. The Company’s patented technology provides clinicians with a powerful tool, which can provide an early warning of compromised blood flow and help target appropriate therapies rapidly and accurately. Data from the Bowman Perfusion Monitor helps guide physicians in implementing effective treatments quickly, creating the potential to improve patient outcomes and lower costs. Hemedex’s technology addresses unmet needs in many clinical areas such as neurocritical care (e.g., TBI, SAH), neurosurgery (e.g., TAO, EC-IC Bypass, Moya Moya), reconstructive surgery and organ transplantation, among others.  For more information, visit www.hemedex.com.

 

Communications Team
Hemedex Inc.
sblair@hemedex.com
617 577 1759 X 46